Advertisement

Acta Neuropathologica

, Volume 121, Issue 4, pp 487–498 | Cite as

Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington’s disease mice

  • Junghee Lee
  • Bela Kosaras
  • Steve J. Del Signore
  • Kerry Cormier
  • Ann McKee
  • Rajiv R. Ratan
  • Neil W. Kowall
  • Hoon Ryu
Original Paper

Abstract

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder. Oxidative damage has been associated with pathological neuronal loss in HD. The therapeutic modulation of oxidative stress and mitochondrial function using low molecular weight compounds may be an important strategy for delaying the onset and slowing the progression of HD. In the present study, we found a marked increase of 4-hydroxy-2-nonenal (4-HNE) adducts, a lipid peroxidation marker, in the caudate and putamen of HD brains and in the striatum of HD mice. Notably, 4-HNE immunoreactivity was colocalized with mutant huntingtin inclusions in the striatal neurons of R6/2 HD mice. Administration of nordihydroguaiaretic acid (NDGA), an antioxidant that functions by inhibiting lipid peroxidation, markedly reduced 4-HNE adduct formation in the nuclear inclusions of R6/2 striatal neurons. NDGA also protected cultured neurons against oxidative stress-induced cell death by improving ATP generation and mitochondrial morphology and function. In addition, NDGA restored mitochondrial membrane potential, mitochondrial structure, and synapse structure in the striatum of R6/2 mice and increased their lifespan. The present findings suggest that further therapeutic studies using NDGA are warranted in HD and other neurodegenerative diseases characterized by increased oxidative stress and altered mitochondrial function.

Keywords

Huntington’s disease Mitochondria Lipid peroxidation 4-Hydroxy-2-nonenal (4-HNE) Neuronal survival 

Notes

Acknowledgments

We thank to Katharine Karr and Yu Jin Hwang for the preparation of manuscript. This study was supported by NIH NS52724 (H.R.).

Supplementary material

401_2010_788_MOESM1_ESM.doc (2.2 mb)
Supplementary material 1 (DOC 2,268 kb)

References

  1. 1.
    Albers DS, Beal MF (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 59:131–154Google Scholar
  2. 2.
    Arteaga S, Andrade-Cetto A, Cárdenas R (2005) Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J Ethnopharmacol 98:231–239PubMedCrossRefGoogle Scholar
  3. 3.
    Beal MF (1995) Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357–366PubMedCrossRefGoogle Scholar
  4. 4.
    Beal MF, Ferrante RJ (2004) Experimental therapeutics in transgenic mouse models of Huntington’s disease. Nat Rev Neurosci 5:373–384PubMedCrossRefGoogle Scholar
  5. 5.
    Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr et al (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2:249–253PubMedCrossRefGoogle Scholar
  6. 6.
    Browne SE, Beal MF (2006) Oxidative damage in Huntington’s disease pathogenesis. Antioxid Redox Signal 8:2061–2073PubMedCrossRefGoogle Scholar
  7. 7.
    Comporti M (1998) Lipid peroxidation and biogenic aldehydes: from the identification of 4-hydroxynonenal to further achievements in biopathology. Free Radic Res 28:623–635PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B et al (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci 23:9418–9427PubMedGoogle Scholar
  9. 9.
    Fischbeck KH (2001) Polyglutamine expansion neurodegenerative disease. Brain Res Bull 56:161–163PubMedCrossRefGoogle Scholar
  10. 10.
    Fujimoto N, Kohta R, Kitamura S, Honda H (2004) Estrogenic activity of an antioxidant, nor dihydroguaiaretic acid (NDGA). Life Sci 74:1417–1425PubMedCrossRefGoogle Scholar
  11. 11.
    Goodman Y, Steiner MR, Steiner SM, Mattson MP (1994) Nordihydroguaiaretic acid protects hippocampal neurons against amyloid beta-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res 654:171–176PubMedCrossRefGoogle Scholar
  12. 12.
    Hall ED, Andrus PK, Oostveen JA, Fleck TJ, Gurney ME (1998) Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res 53:66–77PubMedCrossRefGoogle Scholar
  13. 13.
    Hamaguchi T, Ono K, Murase A, Yamada M (2009) Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 175:2557–2565PubMedCrossRefGoogle Scholar
  14. 14.
    Hersch SM, Ferrante RJ (1997) Neuropathology and pathophysiology of Huntington’s disease. In: Watts RL, Koller WC (eds) Movement disorders: neurologic principles and practice. McGraw-Hill, New York, pp 503–518Google Scholar
  15. 15.
    Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983CrossRefGoogle Scholar
  16. 16.
    Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, Gusella JF, MacDonald ME (2007) Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 3:e135PubMedCrossRefGoogle Scholar
  17. 17.
    Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME et al (1999) Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease. J Neurosci Res 58:515–532PubMedCrossRefGoogle Scholar
  18. 18.
    Li Y, Maher P, Schubert D (1997) A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19:453–463PubMedCrossRefGoogle Scholar
  19. 19.
    Li X, Sapp E, Chase K, Comer-Tierney LA, Masso N, Alexander J, Reeves P, Kegel KB, Valencia A, Esteves M, Aronin N, Difiglia M (2009) Disruption of Rab11 activity in a knock-in mouse model of Huntington’s disease. Neurobiol Dis 36:374–383PubMedCrossRefGoogle Scholar
  20. 20.
    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506PubMedCrossRefGoogle Scholar
  21. 21.
    McGrath LT, McGleenon BM, Brennan S, McColl D, McILroy S, Passmore AP (2001) Increased oxidative stress in Alzheimer’s disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 94:485–490PubMedCrossRefGoogle Scholar
  22. 22.
    Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ et al (2002) Lipid peroxidation in aging brain and Alzheimer’s disease. Free Radic Biol Med 33:620–626PubMedCrossRefGoogle Scholar
  23. 23.
    Neely MD, Sidell KR, Graham DG, Montine TJ (1999) The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem 72:2323–2333PubMedCrossRefGoogle Scholar
  24. 24.
    Neely MD, Boutte A, Milatovic D, Montine TJ (2005) Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. Brain Res 1037:90–98PubMedCrossRefGoogle Scholar
  25. 25.
    Nicholls DG, Ward MW (2000) Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci 23:166–174PubMedCrossRefGoogle Scholar
  26. 26.
    Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H (2002) Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer’s beta-amyloid fibrils in vitro. J Neurochem 81:434–440PubMedCrossRefGoogle Scholar
  27. 27.
    Ono K, Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97:105–115PubMedCrossRefGoogle Scholar
  28. 28.
    Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28:2783–2792PubMedCrossRefGoogle Scholar
  29. 29.
    Oyamada R, Hayashi M, Katoh Y, Tsuchiya K, Mizutani T, Tominaga I et al (2006) Neurofibrillary tangles and deposition of oxidative products in the brain in cases of myotonic dystrophy. Neuropathology 26:107–114PubMedCrossRefGoogle Scholar
  30. 30.
    Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ et al (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5:731–736PubMedGoogle Scholar
  31. 31.
    Qahwash IM, Boire A, Lanning J, Krausz T, Pytel P, Meredith SC (2007) Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity. J Biol Chem 282:36987–36997PubMedCrossRefGoogle Scholar
  32. 32.
    Ratan RR, Ryu H, Lee J, Mwidau A, Neve RL (2002) In vitro model of oxidative stress in cortical neurons. Methods Enzymol 352:183–190PubMedCrossRefGoogle Scholar
  33. 33.
    Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M et al (2003) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an SP1-dependent pathway. Proc Natl Acad Sci USA 100:4281–4286PubMedCrossRefGoogle Scholar
  34. 34.
    Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD et al (2003) SP1 and SP3 are oxidative stress-inducible, anti-death transcription factors in cortical neurons. J Neurosci 23:3597–3606PubMedGoogle Scholar
  35. 35.
    Ryu H, Ferrante RJ (2005) Emerging chemotherapeutic strategies for Huntington’s disease. Expert Opin Emerg Drugs 10:345–363PubMedCrossRefGoogle Scholar
  36. 36.
    Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA et al (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington’s disease. Proc Natl Acad Sci USA 103:19176–19181PubMedCrossRefGoogle Scholar
  37. 37.
    Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr et al (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5:1194–1198PubMedCrossRefGoogle Scholar
  38. 38.
    Schaur RJ (2003) Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol Aspects Med 24:149–159PubMedCrossRefGoogle Scholar
  39. 39.
    Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA et al (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397–407PubMedCrossRefGoogle Scholar
  40. 40.
    Sexton A, McDonald M, Cayla C, Thiemermann C, Ahluwalia A (2007) 12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1. FASEB J 21:2695–2703PubMedCrossRefGoogle Scholar
  41. 41.
    Shishido Y, Furushiro M, Hashimoto S, Yokokura T (2001) Effect of nordihydroguaiaretic acid on behavioral impairment and neuronal cell death after forebrain ischemia. Pharmacol Biochem Behav 69:469–474PubMedCrossRefGoogle Scholar
  42. 42.
    Siegel SJ, Bieschke J, Powers ET, Kelly JW (2007) The oxidative stress metabolite 4 hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46:1503–1510PubMedCrossRefGoogle Scholar
  43. 43.
    Trostchansky A, Lind S, Hodara R, Oe T, Blair IA, Ischiropoulos H et al (2006) Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation. Biochem J 393:343–349PubMedCrossRefGoogle Scholar
  44. 44.
    Truant R, Atwal RS, Burtnik A (2007) Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington’s disease. Prog Neurobiol 83:211–227PubMedCrossRefGoogle Scholar
  45. 45.
    Trushina E, McMurray CT (2007) Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145:1233–1248PubMedCrossRefGoogle Scholar
  46. 46.
    Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577PubMedCrossRefGoogle Scholar
  47. 47.
    Vonsattel JP (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115:55–69PubMedCrossRefGoogle Scholar
  48. 48.
    Zarkovic K (2003) 4-Hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 24:293–303PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Junghee Lee
    • 1
    • 2
  • Bela Kosaras
    • 3
  • Steve J. Del Signore
    • 1
    • 4
  • Kerry Cormier
    • 1
    • 4
  • Ann McKee
    • 1
    • 4
  • Rajiv R. Ratan
    • 5
  • Neil W. Kowall
    • 1
    • 2
  • Hoon Ryu
    • 1
    • 2
  1. 1.Department of Neurology and PathologyBoston University School of MedicineBostonUSA
  2. 2.VA Boston Healthcare SystemBostonUSA
  3. 3.Department of NeurologyBeth Israel Deaconess Medical Center and Harvard Medical SchoolBostonUSA
  4. 4.Bedford VA Medical CenterBedfordUSA
  5. 5.Department of NeurologyWeill Medical College of Cornell University, Burke-Cornell Medical Research InstituteWhite PlainsUSA

Personalised recommendations